Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

ROS1 is the largest receptor tyrosine kinase in the human genome. Rearrangements of the ROS1 gene result in oncogenic ROS1 kinase fusion proteins that are currently the only validated biomarkers for targeted therapy with ROS1 TKIs in patients. While numerous somatic missense mutations in ROS1 exist...

Descripción completa

Detalles Bibliográficos
Autores principales: Iyer, Sudarshan R, Nusser, Kevin, Jones, Kristen, Shinde, Pushkar, Keddy, Clare, Beach, Catherine Z, Aguero, Erin, Force, Jeremy, Shinde, Ujwal, Davare, Monika A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565643/
https://www.ncbi.nlm.nih.gov/pubmed/37587872
http://dx.doi.org/10.15252/emmm.202217367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565643/
https://www.ncbi.nlm.nih.gov/pubmed/37587872
http://dx.doi.org/10.15252/emmm.202217367

Ejemplares similares